NRAS and melanoma: In melanoma, mutations in BRAF V600 (present in 40–60% of patients) or NRAS Q61 (found in about 25%) make these methods particularly effective for analyzing ctDNA in most cases (Table 2 and Figure 1, Figure 2 and Figure 3).